University of California San Francisco
Helen Diller Family Comprehensive Cancer Center

Funding Opportunities

[ LSOs | Intramural Awards | Foundations/Other | NIH Announcements ]

Limited Submission Opportunities

(Applications through LSO office)


Intramural Funding Opportunities

  • Deadline: Jan 31, 2021
    The Cancer Cell Map Initiative (CCMI) has funds to support up to two pilot projects in cancer systems biology. Project proposals are solicited from faculty members at UCSF, UC San Diego and nearby universities and research institutes (within 30 miles of either campus) wishing to develop and apply systems biology approaches to address a compelling biomedical question in cancer in collaboration with CCMI investigators (www.ccmi.org/about/investigators).
  • Deadline: Jan 31, 2021
    Cancer Systems Biology Training Program

    The Cancer Cell Map Initiative (CCMI) is pleased to accept applications for our Cancer Systems Biology Training Program (www.ccmi.org/training-program). Applications are solicited from graduate students, postdoctoral fellows and senior scientists (titles such as project scientist or research scientist) at UCSF or UC San Diego wishing to develop and apply systems biology approaches to address a compelling biomedical question in cancer.
  • Deadline: Feb 1, 2021
    The Cancer League RFA

    The Cancer League’s primary interest is in funding research projects that need seed money to gain traction or to get closer to a clinical trial. In addition, projects that take an existing form of treatment, but make it better or more palatable for the patient population are equally as welcomed. Proposals for patient services will also be considered, though the majority of funding will go towards research projects.
  • Deadline: Feb 1, 2021
    UC Pancreatic Cancer Consortium (UCPCC) SPORE Projects

    The UCPCC is planning another SPORE application submission in September 2021 with new and/or revised projects. SPORE project proposals are distinctly different from either R01 or U01 research mechanisms in that they must be translational. In every SPORE project, the development of new cancer-relevant interventions should include both a laboratory component and a human application (see RFA) that must be performed at some time during the 5-year term of the grant.
  • Deadline: Mar 1, 2021
    UC Pancreatic Cancer Consortium (UCPCC) Collaborative Pilot Project Award

    The UCPCCC will fund a one-year pilot to encourage collaboration between UC campuses, with the expectation that it will lead to submission of a major collaborative grant such as an NIH P01, multi-PI R01, or similar. The goal of this solicitation is to promote the highest quality clinical, basic, or population science with translational potential. Projects must be devoted to the prevention, diagnosis and/or treatment of pancreatic neoplasia. Priority will be given to proposals that provide new approaches to important clinical or population/community challenges, or offer a clear route to a clinical trial.
  • Deadline: Mar 1, 2021
    UCSF Resource Allocation Program (RAP) Spring 2021 Cycle

    RAP offers a single online application process for a variety of intramural grants. Grants of interest include:
    • Cancer and Environmental Health Research Pilot Award ($50,000)
    • Pilot Award for Pancreas Cancer ($50,000)
    • Global Cancer Pilot Award ($40,000)
    • Pilot Award in Precision Imaging of Cancer and Therapy ($50,000)
    • Informing Tobacco Product Regulation ($50,000)
    • Independence Support Award ($50,000)
    • Pilots for Junior Investigators and Established Investigators in Basic and Clinical Sciences ($40,000 - 50,000)

Foundations/Other Sources

  • Deadline: Jan 27, 2021
    AACR Cancer Disparities Research Fellowships

    The AACR Cancer Disparities Research Fellowships represent an effort to encourage and support postdoctoral or clinical research fellows to conduct cancer disparities research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to cancer disparities.
  • Deadline: rolling basis through Jan 31, 2022
    Partnership for Accelerating Cancer Therapies (PACT) Clinical Trials RFA 

    The Foundation for the NIH has issued an RFA for novel biomarkers to support the Partnership for Accelerating Cancer Therapies (PACT). The overall goal for this RFA is to solicit clinical trials to partner with the PACT initiative to provide biospecimens for exploratory deep immunoprofiling analysis, employing this standardized set of biomarker assays. The data from this immunoprofiling, along with the necessary de-identified clinical data from the trials, will be placed into the CIDC to continue to build a large body of standardized immunoprofiling data that can be used to validate existing biomarkers for clinical trial and regulatory use, and importantly, to develop new validated biomarkers for these purposes. Development and validation of these biomarkers will allow the immuno-oncology field to more accurately pair patients with novel immunotherapies being developed.
  • Deadline: April 22, 2021
    NCI/CRUK Cancer Grand Challenges

    The National Cancer Institute (NCI) and Cancer Research UK (CRUK), the world’s leading funders of cancer research, are partnering to fund the Cancer Grand Challenges (CGC) program. Cancer Grand Challenges will fund novel ideas by multidisciplinary research teams from around the world that offer the potential to advance bold cancer research and improve outcomes for people affected by cancer.

NIH Announcements

The following NIH/NCI funding opportunities directly align with HDFCCC goals. If you are a Cancer Center member who is interested in applying and receiving grant writing support, please contact Erin Bank.
To view all NCI funding opportunities, search here